GlassScriptPhysician profile
Michael R Engle
NPI 1356326292
$3,310.87
in general payments reported to CMS, 2019-2025
24 companies · $583 in 2025
The $583 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $71.77 · 2021: $249 · 2022: $808 · 2023: $704 · 2024: $570 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $486.18 | 2021-2025 | |
| Novo Nordisk INC | $370.22 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $368.25 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $327.93 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.66 | 2021-2025 | Jardiance, Stiolto Respimat |
| Glaxosmithkline, LLC. | $223.61 | 2019-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $157.90 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $151.73 | 2019-2025 | Evenity, Repatha, Otezla |
| Axsome Therapeutics, INC. | $125.01 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.97 | 2025 | Caplyta |
| Abbott Laboratories | $107.15 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $95.53 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Pfizer INC. | $90.90 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $77.58 | 2019-2022 | |
| Astellas Pharma US INC | $67.18 | 2022-2024 | Myrbetriq, Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $67.12 | 2021-2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.06 | 2022-2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $27.10 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $19.12 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.49 | 2021 | |
| Lundbeck LLC | $14.49 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $13.39 | 2024 | |
| Amarin Pharma, INC. | $12.09 | 2019 | |
| Allergan, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Engle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.